摘要
Dear Editor,Colorectal cancer(CRC)is a common cancer in China and worldwide[1-2].Immune checkpoint blockade(ICB)has been proven effective for DNA mismatch repairdeficient(dMMR)/microsatellite instability-high(MSIH)CRC[3-10]but not for mismatch repair-proficient(pMMR)/microsatellite stable(MSS)CRC in clinical trials[3].No published data on the real-world application of ICB in CRC exist,and thus,whether the response to ICB in unselected patients is similar to that in patients from published trials remains unclear.
基金
funded by the National Natural Science Foundation of China(81672987,82073329)
the Natural Science Foundation of Guangdong Province(2020A1515011286).
